Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$150K
Filings
14
Firms Hired
2
Active Period
2022–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Joe Fiandra Access to Home Infusion Act of 2023
2023 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: HR 5397
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
Client expense: — · Firm income: $40,000
Matched citations: HR 5539
Further Continuing Appropriations and Other Extensions Act, 2024
2023 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: HR 6363
Joe Fiandra Access to Home Infusion Act of 2023
2023 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: HR 5397
Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease review processes; HR 5539 Orphan Cures Act
Client expense: — · Firm income: $40,000
Matched citations: HR 5539
Further Continuing Appropriations and Other Extensions Act, 2024
2023 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: HR 6363
Joe Fiandra Access to Home Infusion Act of 2023
2023 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act
Client expense: — · Firm income: $40,000
Matched citations: HR 5397
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $30,000 · Firm income: —
Matched citations: HR4472
Making Agricultural Products Locally Essential (MAPLE) Act
2023 · first_quarter · Firm: AMRYT PHARMA
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $30,000 · Firm income: —
Matched citations: HR 7667
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; HR 2617 Consolidated Appropriations Act of 2023; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease flexibilities
Client expense: — · Firm income: $40,000
Matched citations: HR 2617
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; HR 2617 Consolidated Appropriations Act of 2023; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease flexibilities
Client expense: — · Firm income: $40,000
Matched citations: HR 4472
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
2022 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; HR 2617 Consolidated Appropriations Act of 2023; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease flexibilities
Client expense: — · Firm income: $40,000
Matched citations: HR 7640
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR4472
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR 7667
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Client expense: — · Firm income: $40,000
Matched citations: HR 4472
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
2022 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Client expense: — · Firm income: $40,000
Matched citations: HR 7640
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Client expense: — · Firm income: $40,000
Matched citations: HR 7667
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Client expense: — · Firm income: $40,000
Matched citations: S 4348
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR4472
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR 7667
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR4472
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Client expense: $40,000 · Firm income: —
Matched citations: HR 7667
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development
Client expense: — · Firm income: $40,000
Matched citations: HR 4472
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
2022 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development
Client expense: — · Firm income: $40,000
Matched citations: HR 7640
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development
Client expense: — · Firm income: $40,000
Matched citations: HR 7667
Source: Senate LDA